GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22.
Lee SL, Pearce E, Ajnakina O, Johnson S, Lewis G, Mann F, et al. The association between loneliness and depressive symptoms among adults aged 50 years and older: a 12-year population-based cohort study. Lancet Psychiatry. 2021;8:48–57.
Fabbri C, Hagenaars SP, John C, Williams AT, Shrine N, Moles L, et al. Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. Mol Psychiatry. 2021;26:3363–73.
Pain O, Hodgson K, Trubetskoy V, Ripke S, Marshe VS, Adams MJ, et al. Identifying the common genetic basis of antidepressant response. Biol Psychiatry Glob Open Sci. 2022;2:115–26.
23andMe Research Team, Li QS, Tian C, Hinds D. Genome-wide association studies of antidepressant class response and treatment-resistant depression. Transl Psychiatry. 2020;10:360.
Zhang Y, Qi G, Park J-H, Chatterjee N. Estimation of complex effect-size distributions using summary-level statistics from genome-wide association studies across 32 complex traits. Nat Genet. 2018;50:1318–26.
Maranville JC, Cox NJ. Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits. Pharmacogenomics J. 2016;16:388–92.
Grzenda A, Widge AS. Electronic health records and stratified psychiatry: bridge to precision treatment? Neuropsychopharmacology. 2024;49:285–90.
Ostergaard SD, Jensen SOW, Bech P. The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatr Scand. 2011;124:495–6.
Milaneschi Y, Lamers F, Berk M, Penninx BWJH. Depression heterogeneity and its biological underpinnings: toward immunometabolic depression. Biol Psychiatry. 2020;88:369–80.
Badini I, Coleman JRI, Hagenaars SP, Hotopf M, Breen G, Lewis CM, et al. Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption. Psychol Med. 2022;52:726–36.
de Kluiver H, Jansen R, Penninx BWJH, Giltay EJ, Schoevers RA, Milaneschi Y. Metabolomics signatures of depression: the role of symptom profiles. Transl Psychiatry. 2023;13:198.
Beijers L, Wardenaar KJ, van Loo HM, Schoevers RA. Data-driven biological subtypes of depression: systematic review of biological approaches to depression subtyping. Mol Psychiatry. 2019;24:888–900.
Beijers L, van Loo HM, Romeijn J-W, Lamers F, Schoevers RA, Wardenaar KJ. Investigating data-driven biological subtypes of psychiatric disorders using specification-curve analysis. Psychol Med. 2022;52:1089–1100.
Fabbri C, Kasper S, Kautzky A, Zohar J, Souery D, Montgomery S, et al. A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. Transl Psychiatry. 2020;10:50.
Shah SB, Peddada TN, Song C, Mensah M, Sung H, Yavi M, et al. Exome-wide association study of treatment-resistant depression suggests novel treatment targets. Sci Rep. 2023;13:12467.
Kang J, Castro VM, Ripperger M, Venkatesh S, Burstein D, Linnér RK, et al. Genome-wide association study of treatment-resistant depression: shared biology with metabolic traits. Am J Psychiatry. 2024;181:608–19.
Wigmore EM, Hafferty JD, Hall LS, Howard DM, Clarke T-K, Fabbri C, et al. Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP. Pharmacogenomics J. 2020;20:329–41.
Xia C, Amador C, Huffman J, Trochet H, Campbell A, Porteous D, et al. Pedigree- and SNP-associated genetics and recent environment are the major contributors to anthropometric and cardiometabolic trait variation. PLoS Genet. 2016;12:e1005804.
Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–81.
Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, et al. New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics J. 2018;18:413–21.
Fabbri C, Kasper S, Kautzky A, Bartova L, Dold M, Zohar J, et al. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. Br J Psychiatry. 2019;214:36–41.
Li QS, Tian C, Seabrook GR, Drevets WC, Narayan VA. Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response. Transl Psychiatry. 2016;6:e889.
Choi SW, Mak TS-H, O’Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15:2759–72.
Sternat T, Fotinos K, Fine A, Epstein I, Katzman MA. Low hedonic tone and attention-deficit hyperactivity disorder: risk factors for treatment resistance in depressed adults. Neuropsychiatr Dis Treat. 2018;14:2379–87.
Chen M-H, Pan T-L, Hsu J-W, Huang K-L, Su T-P, Li C-T, et al. Attention-deficit hyperactivity disorder comorbidity and antidepressant resistance among patients with major depression: a nationwide longitudinal study. Eur Neuropsychopharmacology. 2016;26:1760–7.
Bron TI, Bijlenga D, Verduijn J, Penninx BWJH, Beekman ATF, Kooij JJS. Prevalence of ADHD symptoms across clinical stages of major depressive disorder. J Affect Disord. 2016;197:29–35.
Vannucchi G, Medda P, Pallucchini A, Bertelli M, Angst J, Azorin J-M, et al. The relationship between attention deficit hyperactivity disorder, bipolarity and mixed features in major depressive patients: evidence from the BRIDGE-II-Mix study. J Affect Disord. 2019;246:346–54.
Correa R, Akiskal H, Gilmer W, Nierenberg AA, Trivedi M, Zisook S. Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? J Affect Disord. 2010;127:10–18.
Sternat T, Katzman MA. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatr Dis Treat. 2016;12:2149–64.
Vanderbilt University Hospitals and Clinics. Community Health Needs Assessment. 2013. https://www.vumc.org/communityhealthimprovement/sites/default/files/VU_CHNA_Report_2013_FINAL_COMBINED_060713_330_1.doc_1.pdf. Accessed 28 June 2024.
Mass General Brigham. 2025. https://www.massgeneralbrigham.org/en. Accessed 16 January 2025.
Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med. 2007;357:1939–45.
Medicare. Does Medicare Cover ECT? 2024. https://www.medicare.org/articles/does-medicare-cover-ect/. Accessed 28 June 2024.
Cai N, Revez JA, Adams MJ, Andlauer TFM, Breen G, Byrne EM, et al. Minimal phenotyping yields genome-wide association signals of low specificity for major depression. Nat Genet. 2020;52:437–47.
Glanville KP, Coleman JRI, Howard DM, Pain O, Hanscombe KB, Jermy B, et al. Multiple measures of depression to enhance validity of major depressive disorder in the UK Biobank. BJPsych Open. 2021;7:e44.
American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders (DSM–5). 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
Perlman K, Benrimoh D, Israel S, Rollins C, Brown E, Tunteng J-F, et al. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. J Affect Disord. 2019;243:503–15.
O’Connor SJ, Hewitt N, Kuc J, Orsini LS. Predictors and risk factors of treatment-resistant depression: a systematic review. J Clin Psychiatry. 2023;85:23r14885.
Fabbri C, Pain O, Hagenaars SP, Lewis CM, Serretti A. Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. Neuropsychopharmacology. 2021;46:1821–9.
Ward J, Lyall LM, Bethlehem RAI, Ferguson A, Strawbridge RJ, Lyall DM, et al. Novel genome-wide associations for anhedonia, genetic correlation with psychiatric disorders, and polygenic association with brain structure. Transl Psychiatry. 2019;9:327.
Nguyen T-D, Harder A, Xiong Y, Kowalec K, Hägg S, Cai N, et al. Genetic heterogeneity and subtypes of major depression. Mol Psychiatry. 2022;27:1667–75.
Milaneschi Y, Lamers F, Peyrot WJ, Abdellaoui A, Willemsen G, Hottenga J-J, et al. Polygenic dissection of major depression clinical heterogeneity. Mol Psychiatry. 2016;21:516–22.
Cutler AJ, Mattingly GW, Maletic V. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Transl Psychiatry. 2023;13:228.
Jun C, Choi Y, Lim SM, Bae S, Hong YS, Kim JE, et al. Disturbance of the glutamatergic system in mood disorders. Exp Neurobiol. 2014;23:28–35.
Broad Institute. Connectivity Map. 2020. https://clue.io.
Edkins AL, Price JT, Pockley AG, Blatch GL. Heat shock proteins as modulators and therapeutic targets of chronic disease: an integrated perspective. Philos Trans R Soc Lond B Biol Sci. 2018;373:20160521.
Li L, Wang L, You Q-D, Xu X-L. Heat shock protein 90 inhibitors: an update on achievements, challenges, and future directions. J Med Chem. 2020;63:1798–822.
Cabron A-S, Borgmeyer U, Richter J, Peisker H, Gutbrod K, Dörmann P, et al. Lack of a protective effect of the Tmem106b ‘protective SNP’ in the Grn knockout mouse model for frontotemporal lobar degeneration. Acta Neuropathol Commun. 2023;11:21.
Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, et al. PPAR-γ agonists for the treatment of major depression: a review. Pharmacopsychiatry. 2017;50:49–55.
Cosgrove KT, Kuplicki R, Savitz J, Burrows K, Simmons WK, Khalsa SS, et al. Impact of ibuprofen and peroxisome proliferator-activated receptor gamma on emotion-related neural activation: a randomized, placebo-controlled trial. Brain Behav Immun. 2021;96:135–42.
Williams LM, Debattista C, Duchemin A-M, Schatzberg AF, Nemeroff CB. Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression. Transl Psychiatry. 2016;6:e799.
Coleman JRI, Peyrot WJ, Purves KL, Davis KAS, Rayner C, Choi SW, et al. Genome-wide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank. Mol Psychiatry. 2020;25:1430–46.
Brailean A, Curtis J, Davis K, Dregan A, Hotopf M. Characteristics, comorbidities, and correlates of atypical depression: evidence from the UK Biobank Mental Health Survey. Psychological Med. 2020;50:1129–38.
McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22:394–412.
Gaynes BN, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37:134–45.
Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, et al. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Mol Psychiatry. 2022;27:1286–99.
Gronemann FH, Jorgensen MB, Nordentoft M, Andersen PK, Osler M. Incidence of, risk factors for, and changes over time in treatment-resistant depression in denmark: a register-based cohort study. J Clin Psychiatry. 2018;79:17m11845.
Jha MK, Wakhlu S, Dronamraju N, Minhajuddin A, Greer TL, Trivedi MH. Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial. J Affect Disord. 2018;234:34–37.
Jha MK, Minhajuddin A, Gadad BS, Greer T, Grannemann B, Soyombo A, et al. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology. 2017;78:105–13.
Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171:1278–86.
Ishtiak-Ahmed K, Musliner KL, Christensen KS, Mortensen EL, Nierenberg AA, Gasse C. Real-World evidence on clinical outcomes of commonly used antidepressants in older adults initiating antidepressants for depression: a nationwide cohort study in Denmark. Am J Psychiatry. 2024;181:47–56.
Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Res. 2018;7:F1000 Faculty Rev-659.
Leave a Reply